Avita Medical Limited manufactures the revolutionary medical device, ReCell – a ‘spray on skin’ used to treat serious burns. This ‘lunchbox sized’ device used at the bedside involves harvesting a postage-sized sample of the patient’s healthy skin in order to grow new healthy cells in a special liquid suspension for spraying onto the wound just 45 minutes or so later. The technology succeeded in receiving FDA approval in September 2018, to positive reaction by investors.
Before being approved, ReCell was CE-approved for use in Europe, so Curious PR provided social media content and activation, plus media relations, to ensure that news about a multi-centre, randomised controlled trial (RCT) involving ReCell would reach key members of the media, and that its significance was understood by medical and consumer audiences, alike. Full page coverage was secured in The Daily Mail’s influential ‘Good Health’ section featuring a toddler-age victim of serious abdominal burns who was successfully treated with ReCell at an NHS hospital by burns surgeon, achieving outstanding cosmetic results. Coverage about the trial results also appeared in Nursing Times.